1. Scrip
  2. >>Therapy Areas

Regulus Rises On HCV Data, But Will Injection Find A Market?

 
• By Mandy Jackson

Regulus Therapeutics Inc. reported positive interim Phase II results for its microRNA-targeting injection RG-101 in a hepatitis C virus (HCV) market that's dominated by highly effective oral drugs, but the company may be able to reach a goal that's been illusive for Gilead Sciences Inc. and its competitors – curing HCV patients with a four-week regimen.

Regulus Therapeutics Inc. reported positive interim Phase II results for its microRNA-targeting injection RG-101 in a hepatitis C virus (HCV) market that's dominated by highly effective oral drugs, but the company may be able to reach a goal that's been illusive for Gilead Sciences Inc. and its competitors – curing HCV patients with a four-week regimen.

San Diego-based Regulus gained 18.5% to close at $7.44 per share after the company said hepatitis C was undetectable in 37 out of 38 patients (97%) eight weeks after starting...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.